Background: Type I and II inosine monophosphate dehydrogenases (IMPDH) are the targets
Introduction
Mycophenolic acid (MPA) is an immunosuppressive drug widely used in liver and kidney transplantation [1] [2] [3] . Its effect is essentially attributed to the inhibition of type II Inosine MonoPhosphate DeHydrogenase (IMPDH) [4] [5] [6] , a rate-limiting enzyme involved in the de novo purine synthesis pathway [7, 8] . Lymphocytes are devoid of the salvage pathway that allows other cells to recycle purines, and are therefore dependent on IMPDH II for DNA synthesis and GMP/AMP controlled pathways [9] . MPA therapy is not devoid of treatment failures and side effects [10] [11] [12] , which indicates inter-individual pharmacokinetic or pharmacodynamic variability. The potential benefit of mycophenolate mofetil (MMF) dose adjustment in decreasing the risk of acute rejection is still controversial, as two studies yielded divergent results [13, 14] . There have been many attempts to identify pharmacogenetic parameters that could be taken into account in order to control MPA pharmacokinetic variability, with limited success so far [15, 16] . As IMPDH I and II are the target proteins of MPA, polymorphisms in their genes might explain part of the interindividual variability in MPA effects [17] . Wang et al. found an association between two intronic IMPDH I SNPs (rs2278293 and rs2278294) and the incidence of BPAR in kidney transplant recipients, and concluded that these IMPDH I polymorphisms should be considered in further pharmacogenetic studies [18] . In a recent study on IMPDH II expression, Vannozzi F et al. identified IMPDH II gene as another good candidate for MPA pharmacogenetic studies [19] . Several studies demonstrated that both isoforms of IMPDH are transcribed in response to T cell activation [11] and that the increase of IMPDH activity is linked to activation of both IMPDH isoforms [20] [21] . (NP_000875.2) [22] . This protein shares 84% homology with IMPDH I and its exonic sequence is highly conserved among species, especially in mammalians [23] . The 3D structure has been published, and crucial amino-acids for the enzyme activity (Cys-331, Asp-364 and Ser-329) and MPA binding site (Ser-276 Thr-333 and Gln-441) have also been reported [22, 23] ). Polymorphisms in these regions could potentially be linked with interindividual variations in MPA effects. A random mutagenesis study has found three IMPDH II mutations (L30F/Q227R, A462T and F465S/D470G) conferring resistance to MPA [24] .
However, none of them have yet been reported in vivo.
Little is known about the consequences of IMPDH II gene polymorphisms and their involvement in patients' response to MPA. Only two non-synonymous polymorphisms are referenced in the NCBI database (the AAG/-rs5848860 deletion and the rs11557540 A/G single nucleotide polymorphism) with no frequency mentioned. A recent study [25] based on genotyping of more than 400 DNA samples reported no mutated allele for these two previously reported polymorphisms (rs5848860 and rs11557540) and suggested these reported polymorphisms to be sequencing artifacts. Using in silico techniques, the same team predicted a possible effect of a mutation in the promoter region (rs4974081) on IMPDH II transcription [25] , which has not yet been confirmed by in vitro or clinical studies. Wang J. et al. reported the previously non-referenced 787C>T SNP in exon 7, leading to a Leu-Phe substitution and a 10-fold decrease in basal enzyme activity in vitro [16] . However, this mutation showed a low frequency (~1%) in the population and the authors were not able to demonstrate any association between this mutation and clinical outcomes [18] . found increased IMPDH activity in variant carriers of the 3757T>C IMPDH II SNP [26] , but no association with acute rejection incidence was found, which may have been due to an underpowered sample size.
The goals of the present study in a large group of renal transplants (n=456) receiving mycophenolate mofetil in combination with calcineurin inhibitors were to look for possible new polymorphisms in exons, the flanking intron-exon regions and the proximal promoter of the IMPDH II gene in 80 renal transplant patients and for associations between clinical outcomes and the previously reported or new IMPDH polymorphisms, taking in account demographic, biological and treatment data as potential confounders.
Material and methods

Patient population:
This study was conducted in adult, de novo renal transplant patients enrolled in the with the approved fixed-dose over the first 12 months posttransplantation. All patients signed a specific written informed consent for pharmacogenetic investigations. The study design, patient populations and primary results were recently reported [13, 14] . Briefly, patients enrolled in Apomygre received MMF in combination with cyclosporine, whereas those in FDCC were either on tacrolimus or cyclosporine (Table 1) . MPA AUC 0-12h , the associated calcineurine inhibitor (CNI), CNI concentrations, side effects (leucopenia, infection, diarrhea), and biopsy proven acute rejection (BPAR) episodes were collected at D7, D14, M1 M3, M6 and M12 post-transplantation in both trials. Leucopenia was defined as a white blood 
DNA samples:
In the FDCC study [27] , genomic DNA was isolated from 200 μl of EDTA whole blood using a total nucleic acid extraction kit (MagNA Pure LC; Roche Diagnostics, Mannheim, Germany). In the Apomygre study, genomic DNA was extracted from EDTAtreated blood using a previously described manual ethanol precipitation method [28] .
DNA from 80 randomly selected APOMYGRE patients were used for IMPDH II sequencing. The genomic DNA samples from 121 APOMYGRE and 335 FDCC patients were genotyped and used for the pharmacogenetic association study.
IMPDH II sequencing:
To tentatively identify novel IMPDH II mutations, 10 targets covering the proximal promoter, 14 exons and intron/exon flanking regions from 80 patients DNA samples were sequenced. Table 2 lists the SNPs identified. Ten genomic DNA regions (target 1 to 10) covering the proximal promoter region, the 14 exons and the flanking intron-exon regions of the IMPDH II gene were PCR-amplified using the AmpliTAQ gold PCR master mix (Applied Biosystems, Courtaboeuf, France) (covered regions are reported in supplemental Table 1 ).
Reactions were carried out in a final volume of 100 µl using 150 ng genomic DNA and 10 µM of reverse and forward primers, designed using the Primer3 website (http://frodo.wi.mit.edu/) and reported in supplemental Table 1 . Amplification consisted of an initial denaturation for 6 minutes at 95°C followed by 35 cycles of denaturation at 95°C for 15
seconds, annealing at 60°C for 15 seconds and extension at 72°C for 1 minute. Terminal elongation was performed at 72°C for 7 minutes. The PCR-amplified products were purified inserm-00494526, version 1 -23 Jun 2010
using the QiaVac96 kit (Qiagen, Courtaboeuf, France) and forward sequenced using the Bigdye terminator v1.1 kit (Applied Biosystems) according to the manufacturers' procedures.
All the potential SNPs were confirmed by reverse sequencing. The extension products were purified using a standard Ethanol/EDTA/sodium acetate precipitation procedure and the nucleotide sequences determined on an ABI 3100 automated sequencer (AppliedBiosystems). The Sequencer v4.8 program (Gene Codes Corp. Ann arbor, MI, US) was used for data processing using the IMPDH II reference sequence (Genbank NC_000003.10) for automatic alignment. All SNPs and unclear regions were visually checked.
Genotyping assays:
The IMPDH II rs11706052 and 787C>T SNPs were genotyped in patients whose DNA had not been sequenced at the previous step. The previously reported rs4974081, rs2278293 and rs2278294 SNPs were genotyped in all 456 patients because IMPDH II rs4974081 was out of our sequencing coverage and both rs2278293 and rs2278294 are located on the IMPDH I gene. Genotyping was performed using validated TaqMan allelic discrimination assays on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems), using the manufacturer protocol.
Statistical analyses:
Deviation from the Hardy-Weinberg equilibrium was investigated for each SNP separately using the Fisher exact test. Statistical analyses were performed using R software Concentration values in the stable period (M6-M12) were used when no events occurred.
Patients were divided into the following categorized groups: below (group 1), within (group 2), or above (group 3) the target range for either CNI concentration (CNI concentration groups) or MPA AUC 0-12h (MPA AUC groups). Target ranges were 30 to 60 mg.h/l for MPA AUC 0-12h ; 1300-1500 (D7-M1), 1100-1300 (M1-M3), 800-1100 (M3-M6) and 700-900 µg/l (M6-M12) for cyclosporine C 2h [13] ; 10-15 µg/l (D7-M3) and 5-15 µg/l (M3-M12) for tacrolimus C 0 [29] . The final multivariate model was determined by stepwise regression.
Variables with p values > 0.20 were not included into the final model; p values < 0.05 in the final model were considered as significant. Linkage disequilibrium estimation and haplotype analysis were performed using the THESIAS program (http://genecanvas.ecgene.net).
Results
IMPDH II polymorphisms:
Within exonic regions, no SNP was detected. Specifically, no variant allele for the two non-synonymous (rs11557540 and rs5848860) or the seven synonymous (rs11557543, rs11557547, rs11557541, rs11557545, rs11557542, rs11557544 and rs11557546) SNPs the 787 C>T (Leu236Phe) and 417 C>T SNPs previously reported by Wang et al. [16] could not be found in these 80 samples. Within the intronic regions sequenced, the SNPs referenced in Genbank were not found either, except for the rs11706052 SNP (i.e., IVS7+10T>C or 3757T>C; Table 2 ), detected in 9.3% of the sequenced alleles (Table 2 ). In addition, we observed, although at low frequencies, 3 previously reported intronic SNPs (IVS1-162C>T:
1.2%; IVS1+91 T>G: 0.6%; and IVS12-23C>T: 2.5%; Table 2 The minor rs4974081 allele located in the IMPDH II distal promoter region was genotyped and found at an allelic frequency of 24% in our 456 patients (Table 3 ). The intronic 3757T>C (rs11706052) SNP detected by gene sequencing was further investigated in the remaining patients by genotyping. The frequency of its variant allele was 9% (Table 3) .
No variant 787C>T (Leu236Phe) allele was found in the group of 456 patients (Table 3) . No linkage disequilibrium was found between IMPDH II rs4974081 and rs11706052 SNPs (r² = 0.02).
IMPDH I polymorphisms:
For the IMPDH I rs2278293 and rs2278294 SNPs, the minor allele frequencies were 46%
and 36%, respectively ( Table 3 For those previously reported, the allelic frequency found here was consistent with the literature: rs4974081, 21% in Caucasians [25] ; 3757T>C (rs11706052) 7-10.2% [15, 16] ;
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787C>T (Leu236Phe) < 1% [16, 26] ; rs2278293 42.7% ; and rs2278294 40.6% [18] . It is noteworthy that the patients' ethnicity or the allelic distribution between ethnic subpopulations was not mentioned in these last four papers.
Association between clinical outcome and genetic, demographic and pharmacologic parameters:
No association was found between the four tested clinical outcomes and any of the Table 4) .
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Haplotype analysis of IMPDH I showed no significant association with the clinical outcomes.
Discussion
We did not discover any new IMPDH II polymorphism in the 80 patients whose DNA was sequenced. In addition, we did not observe the previously reported, non-synonymous IMPDH II polymorphisms rs11557540, rs5848860 and 787C>T. The first two mutations were already indicated as potential sequencing errors by Mohamed et al. [25] who studied a cohort of more than 400 patients, whereas the third (787C>T) polymorphism was found at a low frequency (1% or less) by Wang et al. in two different studies [16, 18] . However, we did not find this last variant allele either when genotyping our 456 DNA samples. This difference may be due to the different ethnical origins of the populations studied. Even though Wang et al. reported that the Leucine to Phenylalanine amino acid change resulting from this SNP induced a drastic decrease in IMPDH II catalytic activity [16] , they also wrote in a second paper that a putative association with leucopenia would be difficult to prove due to its very low frequency [18] . Furthermore, such a rare allele would probably not significantly contribute to clinical management of the MMF benefit/risk balance.
The present sequencing study did not retrieve any mutated allele of the IMPDH II intronic SNPs listed in GenBank, except for rs11706052 (3757T>C) which was present at a frequency similar (9% of our 456 patients) to those reported by Grinyo et al. [15] and Wang et al. [16] .
In our cohort, this SNP was not significantly associated with BPAR, which is consistent with the results previously reported by Wang et al. [18] who found no association in 191 kidney transplant recipients using univariate analysis. However, Grinyo et al [15] did find a significant association between the 3757T>C SNP and BPAR at 3 and 12 months posttransplantation in 237 patients of the CAESAR study. They used multivariate logistic
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regression but only considered a few demographic covariates (age, sex, treatment groupscyclosporine standard dose, low-dose or withdrawal-and donor type), but not MPA dose (that was significantly linked with BPAR in their study) or MPA exposure. They also admitted that they had very few variant allele carriers and that they had no mechanistic explanation for this association. The present study has the largest group of patients prospectively followed for one year post-transplantation so far, and used multivariate logistic regression considering many possible confounders. We were not able to confirm the association between this genotype and acute rejection.
We also found that this 3757T>C SNP was not associated with leucopenia (which was consistent with Wang et al.'s results) [18] , nor with CMV infections or other infections, which were not tested in the other two studies. A recent paper [26] reported a higher IMPDH activity in carriers of the variant 3757T>C SNP, without any association with clinical outcomes. As we did not measure IMPDH activity in the present patient cohort, we were unable to check the functional consequence of this polymorphism.
We were also interested in the promoter variant rs4974081 for which an effect on IMPDH II transcription and thus possibly on MMF effects was forecasted in silico [25] . The variant allele was present in 25% of our 456 patients, but no statistically significant association was
found with any clinical outcome tested. In vitro studies of IMPDH II transcription may give more information about the potential influence of this promoter mutation.
We found three IMPDH II intronic SNPs, which were previously reported by Wang et al [16] at the same low frequencies. These SNPs showed no significant association with patient outcomes. Although the study may have been underpowered to find any significant association with these rare mutated alleles, it is less likely that intronic SNPs have a large influence on MPA pharmacodynamics.
We also investigated two IMPDH I polymorphisms (rs2278293 and rs2278294) which were previously reported to be associated with a decreased risk of BPAR [18] . No association
with either BPAR or other tested outcomes was found for the rs2278293 variant in our large sample of patients. This discrepancy with Wang et al. is not explained by the fact that we did not group heterozygous and homozygous variant carriers (51% and 20% of patients, respectively) to perform our analyses, because when we did there was no significant association between the rs2278293 variant and BPAR either (data not shown). On the other hand, we did find a significant, protective effect on BPAR of the rs2278294 variant allele as compared to the wild-type allele (log-additive model; OR 0.54 95% CI [0.34-0.85]; p = 0.0075; Table 4 ). Nevertheless, no explanation on the mechanism behind this decreased risk of BPAR with an IMPDH I intronic SNP could be inferred. The mutant allele carriers also had a 1.6-fold increased risk of leucopenia, again with a gene-dose effect. The fact that BPAR and leucopenia are inversely associated to the same rs2278294 SNP reinforces the pertinence of this finding. A factor favoring low lymphocyte levels, sometimes leading to leucopenia episodes, is expected to protect the patient from developing an immunological reaction against the allograft.
One limitation of this study is that we missed information about the patients' ethnicity. This is partly due to the fact that the APOMYGRE study was conducted in France, where it is not legally possible to ask patients about their ethnic origins, unless it is the main aim or a main determinant of the study and provided one obtains a special authorization from the ministry of health. However, all patients enrolled in this sub-study were recruited in Europe, which suggests that a vast majority were of European descent, although this cannot be ascertained.
When combined with MPA, cyclosporine was associated with more frequent side effects (leucopenia, CMV and other infections) than tacrolimus, with no difference in acute rejection inserm-00494526, version 1 -23 Jun 2010
incidence. Nevertheless, the association between CNI type and infections could be biased by the fact that all tacrolimus co-treated patient were enrolled in the FDCC trial where reporting infections could have been slightly different from the APOMYGRE trial.
Currently, the benefit of MPA TDM in transplant recipient is still under debate, as highlighted in a recent review by Knight & Morris [30] . Many retrospective studies found significant relationships between MPA AUC 0-12h and BPAR or side effects in various types of populations [31] [32] [33] [34] [35] , but the few prospective studies lead to diverging conclusions. The FDCC study found no statistically significant differences in outcome between the fixed-dose group and the dose-adjusted group [14] , whereas the Apomygre trial did [13] . In the current retrospective study based on patients from these two trials we found statistically significant evidence that being in the target range for both the CNI (whether cyclosporine or tacrolimus)
and MPA strongly protected against acute rejection, with no increased risk of side effects.
Conclusions
We did not find new variant alleles in the IMPDH II gene when sequencing DNA from 80 patients, nor associations between the known IMPDH II polymorphisms and clinical outcome.
We found a significant association of the IMPDH I rs2278294 SNP with BPAR and leucopenia, but the previously reported association between IMPDH I rs2278293 and outcomes was not confirmed. MPA AUC 0-12H < 30 mg.h/L was significantly associated with an increased risk of BPAR, while the nature of and the exposure to the associated CNI were associated with BPAR, and leucopenia.
We thank Jean-Hervé Comte, Marie-Claire Baclet and her team from the sequencing platform for their excellent technical assistance in the sequencing and genotyping part.
inserm-00494526, version 1 -23 Jun 2010 
Target n°1
T1Left GGCTTGGACTGTGAAAAGAAA Proximal Promoter (-500 to -160) T1Right CCGCGCCAATATAAACCA
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